Nubeqa Prescribing Information Updated With New Survival Data

Nubeqa Prescribing Information Updated With New Survival Data

282939

Nubeqa Prescribing Information Updated With New Survival Data

The prescribing information for Nubeqa (darolutamide) — used to treat men with prostate cancer that has not spread to other parts of the body — will be updated to include overall survival data for patients with non-metastatic castration-resistant prostate cancer (nmCRPC), according to Bayer, one of the therapy’s developers. Specifically, data demonstrating that Nubeqa lowers the risk of death by 31% in nmCRPC will now be included in the prescribing information, Bayer announced. In addition,…

You must be logged in to read/download the full post.